Pityriasis Rosea
A common, harmless, self-resolving rash that starts with a single large 'herald patch' followed by a 'Christmas tree' pattern of smaller spots on the torso.
Emergency Management: None.
Pityriasis rosea is an acute, self-limiting papulosquamous skin eruption characterized by a distinct clinical course. It classically begins with a single, large herald patch, followed 1-2 weeks later by a generalized secondary eruption of smaller oval macules and papules following the cleavage lines of the trunk.
Detailed Overview
The condition is harmless but often alarming to patients due to the sudden widespread rash. It is widely considered to be a viral exanthem, strongly linked to systemic reactivation of Human Herpesvirus 6 (HHV-6) and HHV-7. The rash typically lasts 6-8 weeks but can persist for months. It leaves no scars, though post-inflammatory hyperpigmentation or hypopigmentation can occur, particularly in darker skin tones. It is not considered highly contagious.
Epidemiology & Demographics
Common worldwide. Most frequently affects children, adolescents, and young adults (ages 10-35). Slight female predominance. Incidence peaks in the spring and autumn months.
Etiological Mechanism
The exact cause is not definitively proven, but robust evidence points to the endogenous reactivation of HHV-6 and HHV-7. Unlike primary infection (which causes roseola in infants), this is a reactivation event. Certain drugs (e.g., ACE inhibitors, metronidazole, isotretinoin, gold, biologics) can cause a pityriasis rosea-like drug eruption.
Primary Causes
Viral reactivation (HHV-6/7). Immune response to the virus in the skin leads to the characteristic scaly plaques.
Systemic viral reactivation leads to viremia. The virus targets the skin, inducing an inflammatory response. Histologically, there is focal parakeratosis, absence of the granular layer, and spongiosis in the epidermis, with a perivascular lymphocytic infiltrate in the superficial dermis and extravasated red blood cells. The herald patch represents the initial site of intense local inflammation, while the secondary rash represents a generalized immune-mediated delayed hypersensitivity response to the circulating virus.
Diagnostic Criteria & Guidelines
Diagnosis is entirely clinical, based on the characteristic history (herald patch followed by secondary eruption) and morphology (collarette of scale, Christmas tree pattern). No biopsy is needed for classic cases.
Reassurance and symptomatic treatment only. Emollients for dryness. Medium-potency topical corticosteroids (e.g., Triamcinolone 0.1% cream BID for 1-2 weeks) or oral antihistamines (e.g., Cetirizine 10 mg daily) to relieve pruritus.
Second-Line & Adjunctive Therapy
For severe, extensive, or intensely pruritic cases: Oral Acyclovir (800 mg 5 times daily for 1 week) started early in the disease course has been shown to hasten resolution. Narrowband UVB phototherapy can also accelerate clearing but may increase the risk of post-inflammatory hyperpigmentation.
Surgical & Procedural Management
None.
Patient Counseling & Advice
Reassure the patient that the rash is not contagious, not a sign of poor hygiene, and not a dangerous infection. Inform them that it will take 6-8 weeks to go away completely. Warn them about the possibility of temporary dark spots remaining after the rash clears, which will fade over months.
Follow-Up & Monitoring Schedule
No routine follow-up is necessary unless symptoms are refractory, the rash persists beyond 3 months (prompting biopsy to rule out parapsoriasis or cutaneous T-cell lymphoma), or if palm/sole lesions appear.
Preventive Strategies
No known preventive measures.
Excellent. It is a benign, self-limited condition with permanent immunity; recurrence is rare (occurring in about 2% of patients).